Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Dicerna Pharmaceuticals, Inc. (DRNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
37.99-0.01 (-0.03%)
At close: 1:00PM EST
37.97 -0.02 (-0.05%)
After hours: 03:50PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close38.00
Open37.93
Bid37.95 x 1100
Ask38.05 x 1800
Day's Range37.94 - 38.00
52 Week Range19.06 - 40.14
Volume10,938,547
Avg. Volume1,738,211
Market Cap2.96B
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-1.63
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.96
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DRNA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Dicerna Pharmaceuticals, Inc.
    Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to half of the firm's sales are generated in the United States.
    Rating
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more
Advertisement
Advertisement